NCT05905133进行中（未招募）2 期
A Multi-Center, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe Atopic Dermatitis
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 360
- 试验地点
- 38
- 主要终点
- Incidence of treatment-emergent adverse events (TEAEs)
研究概览
简要总结
This study is a single-arm, open-label, multi-center clinical study designed to assess the safety and efficacy of CBP-201 in eligible subjects with moderate to severe Atopic Dermatitis.
详细描述
The study includes a screening period, a treatment period and a follow-up period.
The subjects will receive a subcutaneous injection of CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 ≤ age ≤ 75 years at the screening visit, male or female.
- •Diagnosed with atopic dermatitis (according to the American Academy of Dermatology's Guidelines of care for the management of atopic dermatitis, 2014[1]) at the time of screening, and meeting all the 4 criteria below:
- •Suffering from the disease for more than 1 year at the time of screening;
- •At the screening and baseline visit, IGA score ≥ 3 (according to the validated Investigator Global Assessment for Atopic Dermatitis [vIGA-AD™] scale);
- •EASI score ≥ 12;
- •Percentage of total BSA affected by AD ≥ 10%.
- •Female subjects of childbearing potential (FCBP) and male subjects who have not undergone vasectomy must agree to take highly effective contraceptive measures during the entire study period (from the signing of informed consent forms (ICFs) to the 8-week follow-up period after discontinuation of study drug). Postmenopausal women (determined by testing follicle stimulating hormone [FSH]; defined as the women who have had amenorrhea for at least 12 consecutive months without using drugs known to cause amenorrhea, and have a recorded FSH level greater than 40 mIU/mL or in the postmenopausal range) and women with a record of surgical sterilization (i.e., tubal ligation or hysterectomy or bilateral oophorectomy) before the screening visit can be considered infertile.
- •Highly effective contraceptive measures include:
- •i. Abstinence (acceptable only if it is part of the subject's routine lifestyle); ii. Hormones (oral, patch, ring, injection, implant) combined with male condoms. This measure must be used at least 30 days before the first study drug administration. Otherwise, another acceptable method of contraception must be used; iii. Intrauterine device (IUD) combined with male condoms.
- •Subjects are willing and able to comply with study visits and related procedures.
- •Subjects have the ability to learn the study requirements and process, and voluntarily take part in the clinical trial and sign an ICF.
排除标准
- •Received prior treatment with anti-interleukin-4 receptor α (IL-4Rα)/anti-interleukin-13 (IL-13) antibodies with a poor response (including treatment failure or development of unacceptable treatment-related adverse reactions).
- •Have received any of the following topical treatments within 2 weeks before D1 visit: phosphodiesterase-4 (PDE-4) inhibitors, Janus kinase (JAK) inhibitors, or aromatic hydrocarbon receptor agonists.
- •Have received systemic treatment with corticosteroids (except for corticosteroid inhalers and nasal sprays) or other immunosuppressive/immunomodulatory agents (including but not limited to cyclosporine, mycophenolate mofetil, azathioprine, methotrexate, JAK inhibitors, and various biological agents) within 2 weeks before D1 visit or 5 drug half-lives (if known), whichever is longer.
- •Have received treatment with immune cell depletion agents (e.g., rituximab) within 6 months before D1 visit.
- •Have received any investigational drug/treatment within 4 weeks before D1 visit or 5 drug half-lives (if known), whichever is longer.
- •Other skin complications in addition to AD that may interfere with the study assessments.
- •There is a known or suspected history of immunosuppression/immunodeficiency within 6 months before D1 visit (including but not limited to a history of invasive opportunistic infections, such as aspergillosis, coccidiosis, histoplasmosis, acquired immunodeficiency syndrome (AIDS), listeriosis, or Pneumocystis, even if the infection has subsided), or there is an abnormally frequently recurrent or persistent infection.
- •Received systemic treatment with anti-infective drugs (including but not limited to antibiotics, antiviral drugs, antiparasitic drugs, antiprotozoal drugs, or antifungal drugs) due to acute or chronic infection within 1 week before D1 visit (after the infection subsides, the subjects can be rescreened).
- •History of malignant tumor within 5 years before D1 visit (except for completely cured cervical carcinoma in situ or non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma).
- •History of parasite infection within 6 months before D1 visit.
- •Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and HBV-DNA, or positive for hepatitis C antibody and HCV ribonucleic acid (RNA) polymerase chain reaction, or serologically positive for human immunodeficiency virus (HIV) at the screening visit.
- •Subjects with active tuberculosis, latent tuberculosis, or a history of nontuberculous mycobacterial infection at screening;
- •Unless there is a clear medical record proving that the subject has received adequate treatment and is currently able to start receiving biological treatment (based on the medical judgment of the investigator and/or infectious disease specialist);
- •If needed, an interferon gamma release assay may be used to assist diagnosis of suspected tuberculosis.
- •Any of the following laboratory test abnormalities at the screening visit:
- •Aspartate aminotransferase or alanine aminotransferase > 2 times the upper limit of normal (ULN);
- •Total bilirubin > 1.5 × ULN;
- •Serum creatinine > 1.2 × ULN;
- •White blood cell count < 3.0 × 109/L or ≥ 14 × 109/L; Note: If the subjects have the above laboratory test abnormalities at screening, after being assessed as necessary by the investigator, they are allowed to receive a retest on another day within 28 days of the screening period, and those qualified for the retest are permitted to be enrolled (it is forbidden to conduct drug intervention for those laboratory test abnormalities before retest).
- •History of hypersensitivity to L-histidine, trehalose or Tween (polysorbate) 80, or systemic hypersensitivity reactions to any biological agents (except local injection site reactions).
- •History of alcohol or drug abuse within 2 years before D1 visit.
- •Have been vaccinated with (attenuated) live vaccine within 8 weeks before D1 visit, or planning to be vaccinated during the study period.
- •Planning to undergo major surgical operations during the study period.
- •Pregnant or lactating women, or subjects with pregnancy or lactation plans during the study period.
- •Any other conditions (e.g., those may increase the risks of the subjects, or may affect/interfere with the assessment of the study) that the investigator deems unsuitable for participation in this study, including but not limited to: prior or current physical or mental illness, clinically significant physical examination results, vital signs, or safety laboratory test abnormalities at screening. The specific reasons for subjects excluded due to this criterion will be indicated in the study documents (including medical records and electronic case report form (eCRF)).
研究组 & 干预措施
CBP-201
Experimental
The subjects will receive CBP-201 600 mg (4 mL in total, 2 injections of 2 mL each in different sites) on Day1, begin to receive a subcutaneous injection of CBP-201 300 mg (2 mL) from Week2, and receive CBP-201 300 mg (2 mL) every 2 weeks thereafter until Week10.
干预措施: CBP-201 (Drug)
结局指标
主要结局
Incidence of treatment-emergent adverse events (TEAEs)
时间窗: From Day 1 study drug first administrated to Week 20
cases/person-years
次要结局
- Incidence of treatment-related treatment-emergent adverse events (TEAEs)(From Day 1 study drug first administrated to Week 20)
- Incidence of treatment-related serious adverse events (SAEs)(From Day 1 study drug first administrated to Week 20)
- Incidence of adverse events of special interest (AESIs)(From Day 1 study drug first administrated to Week 20)
- Abnormal changes in vital signs(Pre-dose, Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141)
- Abnormal changes in physical examination(Pre-dose, Day85, Day141)
- Proportion of subjects whose weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) is decreased by ≥ 4 points from baseline(Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141)
- Change and percentage change in the weekly average PP-NRS from baseline(Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141)
- Change and percentage change in the body surface area (BSA) affected by Atopic Dermatitis from baseline(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Change and percentage change in the Dermatology Life Quality Index (DLQI) score from baseline(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects receiving concomitant medications for the treatment of the disease under study (Atopic Dermatitis)(from Day1 to Week12)
- Abnormal changes in laboratory tests: Hematology(Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141)
- Abnormal changes in electrocardiogram (ECG) parameters(Pre-dose, Day1, Day141)
- Proportion of subjects whose Investigator Global Assessment (IGA) score is 0-1 and decreased by ≥ 2 points from baseline(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects whose IGA score is decreased by ≥ 2 points from baseline(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects receiving topical corticosteroids (TCS) for the treatment of the disease under study (Atopic Dermatitis)(from Day1 to Week12)
- Abnormal changes in laboratory tests: Blood biochemistry(Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141)
- Incidence of serious adverse events (SAEs)(From Day 1 study drug first administrated to Week 20)
- Percentage of subjects positive for neutralizing antibody (NAb) in subjects positive for ADA(Day1, Day15, Day29, Day57, Day85, Day141)
- Abnormal changes in laboratory tests: Urinalysis(Pre-dose, Day1, Day15, Day29, Day57, Day85, Day141)
- Proportion of subjects achieving greater than or equal to 75% improvement in Eczema Area and Severity Index (EASI-75)(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects achieving greater than or equal to 50% improvement in Eczema Area and Severity Index (EASI-50)(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects achieving greater than or equal to 90% improvement in Eczema Area and Severity Index (EASI-90)(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects achieving 100% improvement in Eczema Area and Severity Index (EASI-100)(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects with IGA score ≤ 2 (equivalent to reaching a low disease activity state)(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects whose weekly average Peak Pruritus Numerical Rating Scale (PP-NRS) is decreased by ≥ 3 points from baseline(Day1, Day15, Day29, Day43, Day57, Day71, Day85, Day113, Day141)
- Change and percentage change in the EASI score from baseline(Day1, Day15, Day29, Day57, Day85, Day113, Day141)
- Proportion of subjects receiving concomitant medications for the treatment of the disease under study (Atopic Dermatitis) prohibited by the protocol(from Day1 to Week12)
- Duration of TCS use for the treatment of the disease under study (Atopic Dermatitis)(from Day1 to Week12)
- Percentage of subjects positive for anti-drug antibody (ADA) and ADA titer range(Day1, Day15, Day29, Day57, Day85, Day141)
研究者
研究点 (38)
Loading locations...
相似试验
尚未招募
1 期
Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast CancerMetastatic Triple-negative Breast CancerNCT05746728Huihua Xiong45
终止
不适用
Severe OSA Study (SOS)Obstructive Sleep ApneaSleep ApneaNCT05445869ProSomnus Sleep Technologies35
已完成
3 期
Clinical Study to Evaluate the Handling and Safety of AVT06 PFS in Subjects With Chorioretinal Vascular DiseaseChorioretinal Vascular DiseaseNCT05986786Alvotech Swiss AG35
招募中
不适用
A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLPrimary Central Nervous System LymphomaNCT06445257Huai'an First People's Hospital30
进行中（未招募）
不适用
PROACTIVE-HF IDE Trial Heart Failure NYHA Class IIIHeart Failure NYHA Class IIINCT04089059Endotronix, Inc.738